Study identifier:RDEA3170-108
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
A Phase 1, Single-Dose, Open Label, Pharmacokinetic and Pharmacodynamic Study of RDEA3170 in Adult Male Subjects with Mild, Moderate, and Severe Renal Impairment
Gout
Phase 1
No
RDEA3170
Male
32
Interventional
18 Years - 85 Years
Allocation: Randomized
Endpoint Classification: Pharmacokinetics/dynamics Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Basic Science
Verified 01 Nov 2015 by Ardea Biosciences, Inc.
Ardea Biosciences, Inc.
-
No locations available
Arms | Assigned Interventions |
---|---|
Experimental: Cohort 1: Mild renal impairment RDEA3170 15 mg once daily fasted | - |
Experimental: Cohort 2: Moderate renal impairment RDEA3170 15 mg once daily fasted | - |
Experimental: Cohort 3: Severe renal impairment RDEA3170 15 mg once daily fasted | - |
Experimental: Cohort 4: Control subjects with normal renal function RDEA3170 15 mg once daily fasted | - |